You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物:Omicron新冠滅活疫苗臨牀研究需三至四個月完成
阿思達克 04-28 07:12
國藥集團中國生物首席科學家張雲濤在線上媒體溝通會上表示,國藥集團中國生物奧密克戎變異株(Omicron)新冠病毒滅活疫苗近期獲得內地及香港獲得臨牀批件後,將加速開展相關的臨牀研究工作。疫苗的臨牀方案還要跟各位專家和藥監做討論後確定。目前來看,在內地及香港開展臨牀研究,需要三至四個月左右時間完成。 張雲濤表示,新冠病毒的變異是沒有辦法預測的,持續變異確實對疫情防控帶來了巨大挑戰。對於是否要每年接種新冠疫苗,張雲濤表示要基於兩個情況判斷:一個是病毒是不是還在發生持續性的變異,另一個是這種變異是不是根本性的改變。如果有發生重大的變異,仍需通過接種疫苗來防控。(ta/s) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account